Another License out!

On June 23, Huadong Medicine (.

Huadong Medicine said that after the completion of this transaction, liraglutide injection will become the company's second overseas authorized product after TTP273, marking the company's strength in the field of diabetes and its R&D and innovation capabilities have once again been internationally recogniz.

Huadong Medicine Liraglutide Injection (diabetes indication) is the first domestic drug to submit a marketing applicati.

It is worth noting that Huadong Medicine's liraglutide injection for weight loss indications has also completed domestic phase III clinical research, and is expected to submit a listing application at the end of June this ye.

The leader of hypoglycemic drugs "goes to sea" again

According to the International Diabetes Federation (IDF) 2021 report, the Middle East and North Africa (MENA) region has the highest prevalence of adult diabetes in the world, at 46 million, accounting for 12%; it is expected to increase to 13% by 2030, to In 2045, it is estimated that 1 in 8 people will have diabetes; the adult diabetic (20-79 years old) market size is about 6 billion US dolla.

Julphar, which Huadong Medicine has authorized and cooperated with, is one of the largest pharmaceutical manufacturers in the Middle East and Africa and one of the world's leading insulin manufacture.

In this regard, Lu Liang, chairman of Huadong Medicine, said: Julphar and Huadong Medicine are both deeply engaged in the field of diabetes with a large base of patients and wide market dema.

As a leader in diabetes in China, Huadong Medicine has successively gained international recognition for its products under development and its commercialization capabiliti.

Huadong Medicine's liraglutide is expected to be approved within the year, and the research and development progress of hypoglycemic and weight loss indications is the fastest in China

The joint product liraglutide injection is a human glucagon-like peptide-1 (GLP-1) receptor agoni.

GLP-1 drugs represented by liraglutide have shown significant therapeutic effects in weight loss, and the market scale has grown rapid.

Industrial Securities pointed out that Liraglutide currently developed by Huadong Medicine is in the first echelon among domestic manufacture.

In terms of the number and types of product pipelines, Huadong Medicine has more than 20 hypoglycemic drug products commercialized and under developme.

Picture png

Image source: Huadong Medicine

       Caitong Securities pointed out that the diabetes market is a traditional advantageous area of ​​Huadong Medicine’s intensive cultivation for nearly 20 yea.

       From innovative licensein products to reverse licenseout overseas, Huadong Medicine has been continuously cultivating in this field and consolidating its position as an industry leader in consolidating its advantageous position in the diabetes mark.